[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.240.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Cohen  MS, Chen  YQ, McCauley  M,  et al; HPTN 052 Study Team.  Prevention of HIV-1 infection with early antiretroviral therapy.  N Engl J Med. 2011;365(6):493-505. doi:10.1056/NEJMoa1105243PubMedGoogle ScholarCrossref
2.
Grant  RM, Lama  JR, Anderson  PL,  et al; iPrEx Study Team.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.  N Engl J Med. 2010;363(27):2587-2599. doi:10.1056/NEJMoa1011205PubMedGoogle ScholarCrossref
3.
McCormack  S, Dunn  DT, Desai  M,  et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.  Lancet. 2016;387(10013):53-60. doi:10.1016/S0140-6736(15)00056-2PubMedGoogle ScholarCrossref
4.
Molina  JM, Capitant  C, Spire  B,  et al; ANRS IPERGAY Study Group.  On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.  N Engl J Med. 2015;373(23):2237-2246. doi:10.1056/NEJMoa1506273PubMedGoogle ScholarCrossref
5.
World Health Organization. WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP): policy brief. https://www.who.int/hiv/pub/prep/policy-brief-prep-2015/en/. Published November 2015. Accessed April 1, 2019.
6.
Hodges-Mameletzis  I, Dalal  S, Msimanga-Radebe  B, Rodolph  M, Baggaley  R.  Going global: the adoption of the World Health Organization’s enabling recommendation on oral pre-exposure prophylaxis for HIV.  Sex Health. 2018;15(6):489-500. doi:10.1071/SH18125PubMedGoogle ScholarCrossref
7.
Rowley  J, Vander Hoorn  S, Korenromp  E,  et al.  Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.  Bull World Health Organ. 2019;97(8):548-562P. doi:10.2471/BLT.18.228486PubMedGoogle ScholarCrossref
8.
World Health Organization. Sexual health and its linkages to reproductive health: an operational approach. https://www.who.int/reproductivehealth/publications/sexual_health/sh-linkages-rh/en/. Published 2017. Accessed May 2, 2019.
9.
Global Advocacy for HIV Prevention. PrEPWatch. https://www.prepwatch.org/. Accessed April 10, 2019.
10.
Kojima  N, Davey  DJ, Klausner  JD.  Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men.  AIDS. 2016;30(14):2251-2252. doi:10.1097/QAD.0000000000001185PubMedGoogle ScholarCrossref
11.
Traeger  MW, Schroeder  SE, Wright  EJ,  et al.  Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis.  Clin Infect Dis. 2018;67(5):676-686. doi:10.1093/cid/ciy182PubMedGoogle ScholarCrossref
12.
Werner  RN, Gaskins  M, Nast  A, Dressler  C.  Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection—a meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis.  PLoS One. 2018;13(12):e0208107. doi:10.1371/journal.pone.0208107PubMedGoogle Scholar
13.
PRISMA. Preferred Reporting Items for Systematic Reviews and Meta-analyses. http://www.prisma-statement.org/. Accessed April 5, 2019.
14.
Higgins JPT, Green S, eds. Cochrane Training. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. https://training.cochrane.org/handbook. The Cochrane Collaboration. Updated March 2011. Accessed April 5, 2019.
15.
Barendregt  JJ, Doi  SA, Lee  YY, Norman  RE, Vos  T.  Meta-analysis of prevalence.  J Epidemiol Community Health. 2013;67(11):974-978. doi:10.1136/jech-2013-203104PubMedGoogle ScholarCrossref
16.
The World Bank. World Bank country and lending groups. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed May 2, 2019.
17.
Egger  M, Davey Smith  G, Schneider  M, Minder  C.  Bias in meta-analysis detected by a simple, graphical test.  BMJ. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629PubMedGoogle ScholarCrossref
18.
Joanna Briggs Institute. Critical appraisal tools. https://www.joannabriggs.org/research/critical-appraisal-tools.html. Accessed April 2, 2019.
19.
Abrams-Downey  A, Ventuneac  A, Duah  B,  et al.  Risk factors associated with sexually transmitted infections among pre-exposure prophylaxis users in an urban multi-clinic healthcare system.  Open Forum Infect Dis. 2017;4(suppl_1):S668-S669. doi:10.1093/ofid/ofx163.1785Google ScholarCrossref
20.
Aloysius  I, Savage  A, Zdravkov  J,  et al.  InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients.  J Virus Erad. 2017;3(4):218-222.PubMedGoogle Scholar
21.
Anthony  K, Asbel  L, Thompson  F, Madera  RT.  Integrating PrEP for HIV in a categorical STD clinic within a high risk urban setting.  Sex Transm Dis. 2016;43(10)(suppl 2):S132.Google Scholar
22.
Vuylsteke  B, Reyniers  T, Baetselier  ID,  et al. Daily or event-driven PrEP? interim results of “Be-PrEP-Ared,” a PrEP demonstration project among men who have sex with men in Belgium. Paper presented at: 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands.
23.
Baeten  JM, Donnell  D, Ndase  P,  et al; Partners PrEP Study Team.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.  N Engl J Med. 2012;367(5):399-410. doi:10.1056/NEJMoa1108524PubMedGoogle ScholarCrossref
24.
Chaix  ML, Charreau  I, Pintado  C,  et al; ANRS IPERGAY Study Group.  Effect of on-demand oral pre-exposure prophylaxis with tenofovir/emtricitabine on herpes simplex virus-1/2 incidence among men who have sex with men: a substudy of the ANRS IPERGAY trial.  Open Forum Infect Dis. 2018;5(11):ofy295. doi:10.1093/ofid/ofy295PubMedGoogle Scholar
25.
Beymer  MR, DeVost  MA, Weiss  RE,  et al.  Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? a case-crossover study of men who have sex with men in Los Angeles, California.  Sex Transm Infect. 2018;94(6):457-462. doi:10.1136/sextrans-2017-053377PubMedGoogle ScholarCrossref
26.
Bhatia  R, Modali  L, Lowther  M,  et al.  Outcomes of preexposure prophylaxis referrals from public STI clinics and implications for the preexposure prophylaxis continuum.  Sex Transm Dis. 2018;45(1):50-55. doi:10.1097/OLQ.0000000000000690PubMedGoogle ScholarCrossref
27.
Blaylock  JM, Hakre  S, Decker  CF,  et al.  HIV PrEP in the military: experience at a tertiary care military medical center.  Mil Med. 2018;183(3/4)(suppl 1):445-449. doi:10.1093/milmed/usx143PubMedGoogle ScholarCrossref
28.
Bradshaw  H.  Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine in clinical practice and the issues involved.  HIV Med. 2018;19(suppl 2):S57.Google ScholarCrossref
29.
Bristow  C, Moore  DJ, Dube  M,  et al.  Sexually transmitted infections and adherence to PrEPns.  Top Antivir Med. 2018;26(suppl 1):469-470.Google Scholar
30.
Celum  C, Morrow  RA, Donnell  D,  et al.  Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1–uninfected men and women: a subgroup analysis of a randomized trial  [published correction appears in Ann Intern Med. 2016;165(11):832].  Ann Intern Med. 2014;161(1):11-19. doi:10.7326/L16-0549PubMedGoogle ScholarCrossref
31.
Chau  D, Goings  S.  STI rates among PrEP users within a sexual health clinic in Austin, TX.  Sex Transm Dis. 2018;45(suppl 2):S111.Google ScholarCrossref
32.
Cohen  SE, Vittinghoff  E, Bacon  O,  et al.  High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.  J Acquir Immune Defic Syndr. 2015;68(4):439-448. doi:10.1097/QAI.0000000000000479PubMedGoogle ScholarCrossref
33.
Cohen  SE, Vittinghoff  E, Philip  SS, Elion  R, Kolber  MA, Liu  AY.  Repeat rectal gonorrhea and chlamydia infections in a cohort of participants on PrEP.  Sex Transm Dis. 2016;43(10)(suppl 2):S177.Google Scholar
34.
Coyer  L, van Bilsen  W, Bil  J,  et al.  Pre-exposure prophylaxis among men who have sex with men in the Amsterdam Cohort Studies: use, eligibility, and intention to use.  PLoS One. 2018;13(10):e0205663. doi:10.1371/journal.pone.0205663PubMedGoogle Scholar
35.
De Baetselier  I, Smet  H, Wouters  K,  et al.  High level of macrolide resistance of Mycoplasma genitalium found among MSM at high risk for HIV in a Belgian PrEP demonstration project.  AIDS Res Hum Retroviruses. 2018;34(suppl 1):291.Google Scholar
36.
Delany-Moretlwe  S, Chersich  M, Harvey  S,  et al.  Empowerment clubs did not increase PrEP continuation among adolescent girls and young women in South Africa and Tanzania—results from the EMPOWER randomised trial.  J Int AIDS Soc. 2018;21(suppl 6):169.Google Scholar
37.
Elliott  T, Hawkins  L, Proserpio  M, Dosekun  O.  Experience of a PrEP service in a central London sexual health clinic.  HIV Med. 2018;19(suppl 2):S49.Google Scholar
38.
Freeborn  K, Portillo  C, Boyer  CB, Santos  GM.  Misclassification of sexual health risks in a self-identified low risk cohort of men who have sex with men (MSM) enrolled in a community based PrEP program  [published online May 25, 2019].  AIDS Care. doi:10.1080/09540121.2019.1620167Google Scholar
39.
Golub  SA, Pena  S, Fikslin  RA, Goldberg  M, Radix  A.  Partners, not condom use, drive STI rates among PrEP users in community health center.  Top Antivir Med. 2018;26(suppl 1):468.Google Scholar
40.
Grant  RM, Anderson  PL, McMahan  V,  et al; iPrEx Study Team.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.  Lancet Infect Dis. 2014;14(9):820-829. doi:10.1016/S1473-3099(14)70847-3PubMedGoogle ScholarCrossref
41.
Grinsztejn  B, Hoagland  B, Moreira  RI,  et al; PrEP Brasil Study Team.  Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.  Lancet HIV. 2018;5(3):e136-e145. doi:10.1016/S2352-3018(18)30008-0PubMedGoogle ScholarCrossref
42.
Wu  HJ, Strong  C, Ku  SWW,  et al. Syphilis acquisition and dosing schedule for pre-exposure prophylaxis (PrEP) users in Taiwan PrEP demonstration project. Paper presented at: 22nd International AIDS Conference July 23-27, 2018; Amsterdam, the Netherlands.
43.
Hevey  MA, Walsh  JL, Petroll  AE.  PrEP continuation, HIV and STI testing rates, and delivery of preventive care in a clinic-based cohort.  AIDS Educ Prev. 2018;30(5):393-405. doi:10.1521/aeap.2018.30.5.393PubMedGoogle ScholarCrossref
44.
Hojilla  JC.  Optimizing the Delivery of HIV Pre-Exposure Prophylaxis (PrEP): An Evaluation of Risk Compensation, Disengagement, and the PrEP Cascade. San Francisco: School of Nursing, University of California; 2017.
45.
Hoornenborg  E, Coyer  L, van Laarhoven  A,  et al; Amsterdam PrEP Project Team in the HIV Transmission Elimination Amsterdam Initiative.  Change in sexual risk behaviour after 6 months of pre-exposure prophylaxis use: results from the Amsterdam pre-exposure prophylaxis demonstration project.  AIDS. 2018;32(11):1527-1532. doi:10.1097/QAD.0000000000001874PubMedGoogle ScholarCrossref
46.
Hosek  SG, Landovitz  RJ, Kapogiannis  B,  et al.  Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States.  JAMA Pediatr. 2017;171(11):1063-1071. doi:10.1001/jamapediatrics.2017.2007PubMedGoogle ScholarCrossref
47.
Hosek  SG, Rudy  B, Landovitz  R,  et al; Adolescent Trials Network (ATN) for HIVAIDS Interventions.  An HIV preexposure prophylaxis demonstration project and safety study for young MSM.  J Acquir Immune Defic Syndr. 2017;74(1):21-29. doi:10.1097/QAI.0000000000001179PubMedGoogle ScholarCrossref
48.
Irungu  E, Heffron  R, Ngure  K, Baeten  J, Mugo  N.  Unmet need for PrEP among HBV-infected/HIV-uninfected partners in HIV serodiscordant partnerships.  AIDS Res Hum Retroviruses. 2016;32(suppl 1):365.Google Scholar
49.
John  SA, Parsons  JT, Rendina  HJ, Grov  C.  Club drug users had higher odds of reporting a bacterial STI compared with non-club drug users: results from a cross-sectional analysis of gay and bisexual men on HIV pre-exposure prophylaxis.  [published online August 20, 2018].  Sex Transm Infect. doi:10.1136/sextrans-2018-053591PubMedGoogle Scholar
50.
Kenneth  M, Kevin  M, Kenneth  L,  et al. HIV infection and PrEP use are independently associated with increasing diagnoses of bacterial sexually transmitted infections (BSTI) in men accessing care at a Boston community health center (CHC): 2005-2015. http://www.natap.org/2016/IDSA/IDSA_25.htm. Accessed March 14, 2019.
51.
Kipyego  J, Kaguirie  E, Ballidawa  JB,  et al.  Prevalence and correlates of sexually transmitted infections (STIs) among HIV-1 sero-discordant couples in Western, Kenya.  AIDS Res Hum Retroviruses. 2016;32(suppl 1):278.Google Scholar
52.
Knapper  C, Birley  H, Couzens  Z, Parker  I, Jones  A.  Comorbidity, polypharmacy and renal impairment: the experience of managing a PrEP cohort in an integrated sexual health service setting.  HIV Med. 2018;19(suppl 2):S47.Google Scholar
53.
Cotte  L, Veyer  D, Charreau  I,  et al. Anal, oral and genital distribution of HPV in PrEP-users MSM: results at baseline of the ANRS IPERGAY HPV Sub-Study. Paper presented at: 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands.
54.
Lal  L, Audsley  J, Murphy  DA,  et al; VicPrEP Study Team.  Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users.  AIDS. 2017;31(12):1709-1714. doi:10.1097/QAD.0000000000001519PubMedGoogle ScholarCrossref
55.
Lalley-Chareczko  L, Clark  D, Conyngham  C,  et al.  Delivery of TDF/FTC for pre-exposure prophylaxis to prevent HIV-1 acquisition in young adult men who have sex with men and transgender women of color using a urine adherence assay.  J Acquir Immune Defic Syndr. 2018;79(2):173-178. doi:10.1097/QAI.0000000000001772PubMedGoogle ScholarCrossref
56.
Liu  AY, Cohen  SE, Vittinghoff  E,  et al.  Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services.  JAMA Intern Med. 2016;176(1):75-84. doi:10.1001/jamainternmed.2015.4683PubMedGoogle ScholarCrossref
57.
La Fata  L, Cotte  L, Godinot  M,  et al.  High rate of asymptomatic bacterial sexually transmitted infections (STIs) in men who have sex with men on pre exposure prophylaxis (PrEP).  Open Forum Infect Dis. 2017;4(suppl_1):S669. doi:10.1093/ofid/ofx163.1786Google ScholarCrossref
58.
Marcus  JL, Glidden  DV, Mayer  KH,  et al.  No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.  PLoS One. 2013;8(12):e81997. doi:10.1371/journal.pone.0081997PubMedGoogle Scholar
59.
Marcus  JL, Glidden  DV, McMahan  V,  et al.  Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.  PLoS One. 2014;9(3):e91513. doi:10.1371/journal.pone.0091513PubMedGoogle Scholar
60.
Marcus  JL, Hurley  LB, Hare  CB,  et al.  Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation.  J Acquir Immune Defic Syndr. 2016;73(5):540-546. doi:10.1097/QAI.0000000000001129PubMedGoogle ScholarCrossref
61.
Mayer  KH, Maloney  KM, Levine  K,  et al.  Sociodemographic and clinical factors associated with increasing bacterial sexually transmitted infection diagnoses in men who have sex with men accessing care at a Boston community health center (2005-2015).  Open Forum Infect Dis. 2017;4(4):ofx214. doi:10.1093/ofid/ofx214PubMedGoogle Scholar
62.
McCormack  S, Dunn  D.  Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD Study.  Top Antivir Med. 2015;23(E-1):9-10.Google Scholar
63.
Molina  JM, Charreau  I, Chidiac  C,  et al; ANRS IPERGAY Study Group.  Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.  Lancet Infect Dis. 2018;18(3):308-317. doi:10.1016/S1473-3099(17)30725-9PubMedGoogle ScholarCrossref
64.
Molina  JM, Charreau  I, Spire  B,  et al; ANRS IPERGAY Study Group.  Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.  Lancet HIV. 2017;4(9):e402-e410. doi:10.1016/S2352-3018(17)30089-9PubMedGoogle ScholarCrossref
65.
Nguyen  VK, Greenwald  ZR, Trottier  H,  et al.  Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV.  AIDS. 2018;32(4):523-530. doi:10.1097/QAD.0000000000001718PubMedGoogle Scholar
66.
Nguyen  VK, Trottier  H, Tossa  HG,  et al.  Increased rate of C trachomatis infection after being prescribed PrEP.  J Int AIDS Soc. 2016;19(8)(suppl 7):27-28.Google Scholar
67.
Noret  M, Balavoine  S, Pintado  C,  et al.  Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.  AIDS. 2018;32(15):2161-2169. doi:10.1097/QAD.0000000000001939PubMedGoogle ScholarCrossref
68.
Phanuphak  N, Sungsing  T, Jantarapakde  J,  et al.  Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand.  Sex Health. 2018;15(6):542-555. doi:10.1071/SH18065PubMedGoogle ScholarCrossref
69.
Hechter  R, Chen  LH, Yu  K. Healthcare utilization and STI incidence in young men on pre-exposure prophylaxis (PrEP) compared to young men who are not on PrEP: the PrEPARE Study. Paper presented at: 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands.
70.
Reyniers  T, Nöstlinger  C, Laga  M,  et al.  Choosing between daily and event-driven pre-exposure prophylaxis: results of a Belgian PrEP demonstration project.  J Acquir Immune Defic Syndr. 2018;79(2):186-194. doi:10.1097/QAI.0000000000001791PubMedGoogle ScholarCrossref
71.
Solomon  MM, Mayer  KH, Glidden  DV,  et al; iPrEx Study Team.  Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.  Clin Infect Dis. 2014;59(7):1020-1026. doi:10.1093/cid/ciu450PubMedGoogle ScholarCrossref
72.
Tabidze  I, Rusie  L, Hendry  C, Baker  KK.  Primary and secondary syphilis and pre exposure prophylaxis (PrEP), Chicago, IL, 2014-2016.  Sex Transm Dis. 2018;45(suppl 2):S74.Google Scholar
73.
Tiberio  PJ, Williams  K, Barakat  LA, Edelman  EJ, Virata  M, Ogbuagu  O.  Prepared: implementation of a pre-exposure prophylaxis (PrEP) program in a hospital-based HIV clinic.  J Gen Intern Med. 2016;31(2)(suppl 1):S904-S905.Google Scholar
74.
Tiraboschi  J, Brodnicki  E, Brady  M,  et al.  Acute hepatitis C in the PROUD pilot study.  HIV Med. 2014;15(suppl 3):S16.Google Scholar
75.
Traeger  M, Asselin  J, Price  B,  et al.  Changes, patterns and predictors of sexually transmitted infections in gay and bisexual men using PrEP: interim analysis from the PrEPX demonstration study.  J Int AIDS Soc. 2018;21(suppl 6):80.Google Scholar
76.
Volk  JE, Marcus  JL, Phengrasamy  T,  et al.  No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting.  Clin Infect Dis. 2015;61(10):1601-1603. doi:10.1093/cid/civ778PubMedGoogle ScholarCrossref
77.
Zablotska  I, Vaccher  S, Gianacas  C,  et al.  STI rates among gay men taking daily antiretrovirals for pre-exposure prophylaxis of HIV: the NSW demonstration project prelude.  Sex Transm Infect. 2015;91(suppl 2):A78. doi:10.1136/sextrans-2015-052270.209Google ScholarCrossref
78.
Cotte  L, Cua  E, Reynes  J,  et al; Dat’AIDS Study Group.  Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men.  Liver Int. 2018;38(10):1736-1740. doi:10.1111/liv.13922PubMedGoogle ScholarCrossref
79.
Hoornenborg  E, Coyer  L, Achterbergh  R,  et al.  High incidence of hepatitis C virus (re-)infections among PrEP users in the Netherlands: implications for prevention, monitoring and treatment.  J Viral Hepat. 2018;25:192. doi:10.1111/jvh.03_12935Google Scholar
80.
Celum  C, Delany-Moretlwe  S, Hosek  S,  et al. Risk behavior, perception, and reasons for PrEP among young African women in HPTN 082. Paper presented at: 2019 Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, WA.
81.
Hoornenborg  E, Achterbergh  RC, van der Loeff  MFS,  et al; Amsterdam PrEP Project Team in the HIV Transmission Elimination AMsterdam Initiative.  Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.  J Int AIDS Soc. 2018;21(3):e25105. doi:10.1002/jia2.25105PubMedGoogle Scholar
82.
Montaño  MA, Dombrowski  JC, Dasgupta  S,  et al.  Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting.  AIDS Behav. 2019;23(2):548-555. doi:10.1007/s10461-018-2252-9PubMedGoogle ScholarCrossref
83.
Page  K, Akolo  O, Redd  R,  et al.  Baseline sexually transmitted infections (STI) and patient retention among patients enrolling in PrEP in the Baltimore City Health Department sexual health clinic.  Sex Transm Dis. 2018;45(suppl 2):S64.Google Scholar
84.
Parsons  J, Rendina  HJ, Whitfield  T, Grov  C.  Changes in rectal STI incidence and behavioral HIV risk before, during, and after PrEP in a national sample of gay and bisexual men in the United States.  J Int AIDS Soc. 2018;21(suppl 6):14.Google Scholar
85.
Antonucci  S, Desai  M, Dolling  D,  et al. The UK PROUD PrEP Pilot Study: a baseline analysis. Paper presented at: 20th International AIDS Conference; July 20-25, 2014; Melbourne, Australia.
86.
Volk  JE, Marcus  JL, Phengrasamy  T, Hare  CB.  Incident hepatitis C virus infections among users of HIV preexposure prophylaxis in a clinical practice setting.  Clin Infect Dis. 2015;60(11):1728-1729. doi:10.1093/cid/civ129PubMedGoogle ScholarCrossref
87.
Jenness  SM, Weiss  KM, Goodreau  SM,  et al.  Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study.  Clin Infect Dis. 2017;65(5):712-718. doi:10.1093/cid/cix439PubMedGoogle ScholarCrossref
88.
Chow  EPF, Callander  D, Fairley  CK,  et al; ACCESS Collaboration.  Increased syphilis testing of men who have sex with men: greater detection of asymptomatic early syphilis and relative reduction in secondary syphilis.  Clin Infect Dis. 2017;65(3):389-395. doi:10.1093/cid/cix326PubMedGoogle ScholarCrossref
89.
Unitaid. Market and technology landscape: HIV rapid diagnostic tests for self-testing, 4th edition. http://www.unitaid.org/assets/HIVST-landscape-report.pdf. Published July 2018. Accessed April 2, 2019.
90.
Patton  ME, Kidd  S, Llata  E,  et al.  Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010-2012.  Clin Infect Dis. 2014;58(11):1564-1570. doi:10.1093/cid/ciu184PubMedGoogle ScholarCrossref
91.
Sultan  B, White  JA, Fish  R,  et al.  The “3 in 1” Study: pooling self-taken pharyngeal, urethral, and rectal samples into a single sample for analysis for detection of Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men.  J Clin Microbiol. 2016;54(3):650-656. doi:10.1128/JCM.02460-15PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    Infectious Diseases
    December 11, 2019

    Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis

    Author Affiliations
    • 1Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
    • 2Central Clinical School, Monash University, Melbourne, Victoria, Australia
    • 3Department of HIV, World Health Organization, Geneva, Switzerland
    • 4Community Health and Research Division, Eastern Virginia Medical School, Norfolk
    • 5Division of Epidemiology and Community Health, University of Minnesota Twin Cities, Minneapolis
    JAMA Netw Open. 2019;2(12):e1917134. doi:10.1001/jamanetworkopen.2019.17134
    Key Points español 中文 (chinese)

    Question  What is the burden of sexually transmitted infections among individuals using preexposure prophylaxis (emtricitabine and tenofovir disoproxil fumarate) for the prevention of HIV infection?

    Findings  This systematic review and meta-analysis identified 88 studies (71 published and 17 unpublished), with 26 (30%) from low- and middle-income countries. For studies reporting a composite outcome of chlamydia, gonorrhea, and early syphilis, the pooled prevalence was 23.9% at initiation of HIV preexposure prophylaxis, and the pooled incidence was 72.2 per 100 person-years during HIV preexposure prophylaxis.

    Meaning  These estimates indicate a high burden of sexually transmitted infections among individuals initiating preexposure prophylaxis and persistent users of preexposure prophylaxis for the prevention of HIV infection, highlighting the opportunities for active integration of services for sexually transmitted infections and HIV preexposure prophylaxis.

    Abstract

    Importance  Despite a global increase in sexually transmitted infections (STIs), there is limited focus and investment in STI management within HIV programs, in which risks for STIs are likely to be elevated.

    Objective  To estimate the prevalence of STIs at initiation of HIV preexposure prophylaxis (PrEP; emtricitabine and tenofovir disoproxil fumarate) and the incidence of STIs during PrEP use.

    Data Sources  Nine databases were searched up to November 20, 2018, without language restrictions. The implementers of PrEP were also approached for additional unpublished data.

    Study Selection  Studies reporting STI prevalence and/or incidence among PrEP users were included.

    Data Extraction and Synthesis  Data were extracted independently by at least 2 reviewers. The methodological quality of studies was assessed using the Joanna Briggs Institute critical assessment tool for prevalence and incidence studies. Random-effects meta-analysis was performed.

    Main Outcomes and Measures  Pooled STI prevalence (ie, within 3 months of PrEP initiation) and STI incidence (ie, during PrEP use, after 3 months).

    Results  Of the 3325 articles identified, 88 were included (71 published and 17 unpublished). Data came from 26 countries; 62 studies (70%) were from high-income countries, and 58 studies (66%) were from programs only for men who have sex with men. In studies reporting a composite outcome of chlamydia, gonorrhea, and early syphilis, the pooled prevalence was 23.9% (95% CI, 18.6%-29.6%) before starting PrEP. The prevalence of the STI pathogen by anatomical site showed that prevalence was highest in the anorectum (chlamydia, 8.5% [95% CI, 6.3%-11.0%]; gonorrhea, 9.3% [95% CI, 4.7%-15.2%]) compared with genital sites (chlamydia, 4.0% [95% CI, 2.0%-6.6%]; gonorrhea, 2.1% [95% CI, 0.9%-3.7%]) and oropharyngeal sites (chlamydia, 2.4% [95% CI, 0.9%-4.5%]; gonorrhea, 4.9% [95% CI, 1.9%-9.1%]). The pooled incidence of studies reporting the composite outcome of chlamydia, gonorrhea, and early syphilis was 72.2 per 100 person-years (95% CI, 60.5-86.2 per 100 person-years).

    Conclusions and Relevance  Given the high burden of STIs among individuals initiating PrEP as well as persistent users of PrEP, this study highlights the need for active integration of HIV and STI services for an at-risk and underserved population.

    ×